Meliglix 50 Mg

Sitagliptin, the active ingredient in Meliglix 50 Mg, is a DPP‑4 inhibitor presented as a 50 mg tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used with diet and exercise.

GNH USA supplies Meliglix 50 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products sourced from the European Union market. The company ensures quality assurance through rigorous testing and regulatory compliance.

Sitagliptin is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose.

- Type 2 diabetes mellitus (monotherapy): reduces fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combined with metformin): provides additional HbA1c reduction. - Type 2 diabetes mellitus (combined with other antidiabetics): supports overall glycemic management.

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: cough, sore throat, or congestion. - Urinary tract infection: dysuria, frequency, or urgency. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhoea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain possibly radiating to the back. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Severe joint pain: unexplained arthralgia requiring medical evaluation. - Bullous pemphigoid: blistering skin disorder. - Hepatic failure: signs of liver dysfunction such as jaundice.

When prescribing sitagliptin, clinicians should consider several safety aspects.

- Renal impairment: dose adjustment may be required based on estimated glomerular filtration rate. - Hepatic impairment: use with caution; monitor liver function tests. - History of pancreatitis: avoid use or discontinue if symptoms recur. - Concomitant insulin or sulfonylureas: monitor for hypoglycaemia and adjust doses accordingly. - Pregnancy and breastfeeding: safety not established; discuss risks with a healthcare professional. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise plasma concentrations. - Insulin or sulfonylureas: increased risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may reduce glucose‑lowering effect. - Rifampin: may decrease sitagliptin plasma levels. - ACE inhibitors: monitor renal function and electrolytes.